Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tivanisiran (SYL1001) is a siRNA developed specifically to inhibit the expression of transient receptor potential vanilloid 1 (TRPV1) to explore its implications in dry eye disease research.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
10 mg | Inquiry | $ 954.00 |
Description | Tivanisiran (SYL1001) is a siRNA developed specifically to inhibit the expression of transient receptor potential vanilloid 1 (TRPV1) to explore its implications in dry eye disease research. |
In vitro | In vitro studies demonstrated that tivanisiran transfection results in a significant reduction, specifically a 50-60% decrease, in TRPV1 mRNA levels[1][2]. |
Synonyms | SYL1001, Tivanisiran |
Molecular Weight | N/A |
CAS No. | 1848224-71-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Tivanisiran 1848224-71-4 SYL1001 SYL-1001 SYL 1001 inhibitor inhibit